GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sunesis Pharmaceuticals Inc (NAS:SNSS) » Definitions » Cyclically Adjusted Revenue per Share

Sunesis Pharmaceuticals (Sunesis Pharmaceuticals) Cyclically Adjusted Revenue per Share : $0.00 (As of Dec. 2020)


View and export this data going back to 2005. Start your Free Trial

What is Sunesis Pharmaceuticals Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Sunesis Pharmaceuticals's adjusted revenue per share for the three months ended in Dec. 2020 was $0.000. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.00 for the trailing ten years ended in Dec. 2020.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2024-05-05), Sunesis Pharmaceuticals's current stock price is $5.32. Sunesis Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2020 was $0.00. Sunesis Pharmaceuticals's Cyclically Adjusted PS Ratio of today is .


Sunesis Pharmaceuticals Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Sunesis Pharmaceuticals's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sunesis Pharmaceuticals Cyclically Adjusted Revenue per Share Chart

Sunesis Pharmaceuticals Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Sunesis Pharmaceuticals Quarterly Data
Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Sunesis Pharmaceuticals's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Sunesis Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sunesis Pharmaceuticals's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sunesis Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Sunesis Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.



Sunesis Pharmaceuticals Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Sunesis Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Dec. 2020 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2020 (Change)*Current CPI (Dec. 2020)
=0/109.8968*109.8968
=0.000

Current CPI (Dec. 2020) = 109.8968.

Sunesis Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201103 17.544 94.283 20.449
201106 0.000 95.235 0.000
201109 4.505 95.727 5.172
201112 0.000 95.213 0.000
201203 0.000 96.783 0.000
201206 6.667 96.819 7.568
201209 1.173 97.633 1.320
201212 8.118 96.871 9.210
201303 8.085 98.209 9.047
201306 7.831 98.518 8.735
201309 7.831 98.790 8.711
201312 7.709 98.326 8.616
201403 7.444 99.695 8.206
201406 6.742 100.560 7.368
201409 2.965 100.428 3.245
201412 2.732 99.070 3.031
201503 2.652 99.621 2.926
201506 2.475 100.684 2.701
201509 1.919 100.392 2.101
201512 1.836 99.792 2.022
201603 1.550 100.470 1.695
201606 1.473 101.688 1.592
201609 1.473 101.861 1.589
201612 1.225 101.863 1.322
201703 1.113 102.862 1.189
201706 0.000 103.349 0.000
201709 0.000 104.136 0.000
201712 0.000 104.011 0.000
201803 0.242 105.290 0.253
201806 0.000 106.317 0.000
201809 0.000 106.507 0.000
201812 0.000 105.998 0.000
201903 0.000 107.251 0.000
201906 0.000 108.070 0.000
201909 0.000 108.329 0.000
201912 0.650 108.420 0.659
202003 0.038 108.902 0.038
202006 0.000 108.767 0.000
202009 0.000 109.815 0.000
202012 0.000 109.897 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Sunesis Pharmaceuticals  (NAS:SNSS) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Sunesis Pharmaceuticals Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Sunesis Pharmaceuticals's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Sunesis Pharmaceuticals (Sunesis Pharmaceuticals) Business Description

Industry
Traded in Other Exchanges
N/A
Address
395 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080
Sunesis Pharmaceuticals Inc is a US-based biopharmaceutical company. It focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The product portfolio of the company includes Vosaroxin which is an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML). The company's other kinase inhibitor pipeline includes TAK-580, SNS-062, and SNS-229. Further, the firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The firm derives substantially the majority of revenue from license and collaboration agreements.
Executives
Steve Carchedi director 210 BROADWAY, STE 201, CAMBRIDGE MA 02139
Nicole Onetto director 58 S SERVICE RD, MELVILLE NY 11747
Henry Ward Wolff director 6701 KAISER DRIVE, FREMONT CA 94555
Steven B Ketchum director 2483 EAST BAYSHORE ROAD, SUITE 100, PALO ALTO CA 94303
James W Young director
Homer L Pearce director 84 CLIFDEN, ZIONSVILLE IN 46077
Dayton Misfeldt director, officer: See Remarks C/O BAY CITY CAPITAL LLC, 750 BATTERY STREET, SUITE 400, SAN FRANCISCO CA 94111
David C Stump director
Tina Gullotta officer: VP, Finance SUNESIS PHARMACEUTICALS,INC, 395 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
William P. Quinn officer: See Remarks SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BOULEVARD, SUITE 400, SOUTH SAN FRANCISCO CA 94080
Judith A. Fox officer: See Remarks SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BOULEVARD, SUITE 400, SOUTH SAN FRANCISCO CA 94080
Aisling Capital Iv, Lp 10 percent owner 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Andrew N Schiff 10 percent owner PLANET ZANETT INC, 135 E 57TH ST, NEW YORK NY 10022
Steve Elms 10 percent owner 888 SEVENTH AVE, 29TH FL, NEW YORK NY 10106
Aisling Capital Partners Iv Llc 10 percent owner 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106

Sunesis Pharmaceuticals (Sunesis Pharmaceuticals) Headlines